Analogously, KRAS inhibitors (Sotorasib) targeting the G12C mutation and eprenetapopt (APR-246), a novel drug for Tp53-mutant MDS and AML, both are representatives of this molecules. The gene discussed is TP53; the disease is acute myeloid leukemia.